• Revenue of US$3.4 million, consistent with prior year
• Product revenue up 300% to US$1.2 million
• Exclusive US$317 million distribution deal for FebriDx in the US
• FebriDx CLIA waiver submission lodged with FDA
• Cash balance of US$4.5 million, up US$2.5 million

Lumos Diagnostics recorded unaudited revenue of US$3.4 million for Q1 FY26, consistent with the prior year. Revenue from the Services business was US$2.2 million, down from US$3.1 million in the prior corresponding period, primarily due to reduced monthly revenue recognition from the Hologic IP Agreement. Product revenue grew 300% to US$1.2 million, including a US$1.0 million exclusivity fee from the PHASE Scientific distribution agreement for FebriDx. The company signed a pivotal US$317 million exclusive distribution agreement for FebriDx in the US with PHASE Scientific and submitted the FebriDx CLIA waiver application to the FDA, which demonstrated strong performance. The Hologic fFN development project continues, with two additional scopes of work added. Lumos also secured a US$1.5 million contract with Aptatek Biosciences to advance their PheCheck in-home monitoring device for phenylketonuria. The company ended the quarter with a cash balance of US$4.5 million, up US$2.5 million from June 30, 2025, and secured a US$3.3 million loan facility from major shareholders to support working capital needs.

Lumos expects to receive feedback from the FDA on the FebriDx CLIA waiver application between November 2025 and February 2026.

Lumos remains focused on key priorities, including the FDA decision on the FebriDx CLIA waiver, implementing the PHASE Scientific distribution agreement, progressing the BARDA-supported FebriDx pediatric study, and delivering on the Hologic fFN development milestones. The company also aims to progress the first Lumos-branded women's health diagnostic test to formal product development.